Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene
- PMID: 37971500
- DOI: 10.1007/s00259-023-06508-6
Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene
Abstract
Purpose: Chimeric antigen receptor (CAR) T cell therapy has achieved great success in treating hematologic malignancies. However, it is yet to prove effective in the treatment of solid tumors. Thus, it is necessary to develop appropriate methodology for the long-term, accurate, and quantitative evaluation of the distribution and activities of CAR T cells in solid tumors. In the present study, we engineered TfR ΔPSMA CAR (CAR-ΔPSMA) T cells, which targeted the transferrin receptor (TfR) expressed by tumor cells and could be tracked in vivo via a reporter gene encoding the truncated prostate specific membrane antigen (ΔPSMA). We then quantitatively monitored these CAR T cells in vitro and in vivo using [68Ga]Ga-PSMA-617 positron emission tomography (PET)/computed tomography (CT).
Methods: The CAR-ΔPSMA T cells were genetically engineered by transducing T cells with a lentiviral vector encoding TfR41BBζ-T2A-ΔPSMA. Firstly, the target expression, activation, and cytotoxicity of CAR-ΔPSMA T cells were validated in vitro. Secondly, the minimum thresholds of CAR-ΔPSMA T cells detection for [68Ga]Ga-PSMA-617 PET/CT were also determined in vitro and in vivo respectively. Lastly, the feasibility of monitoring the biodistribution and infiltration of CAR-ΔPSMA T cells after systematic administration was evaluated in the breast cancer subcutaneous xenograft model.
Results: The CAR-ΔPSMA T cells retained activation and tumor killing capacity after transduction of the ΔPSMA-encoding reporter gene. Next, the CAR-ΔPSMA T cells could be reliably tracked by [68Ga]Ga-PSMA-617 PET/CT, the detection sensitivity of which was 250 cells/mm3 in vitro and 100 cells/mm3 in vivo. Next, the sequential imaging assays revealed that [68Ga]Ga-PSMA-617 PET/CT could be used to specifically visualize ΔPSMA+ CAR T cells at the tumor site. The increase in the [68Ga]Ga-PSMA-617 signal intensity over time allowed us to effectively detect CAR T cells in vivo.
Conclusion: Our findings preliminarily confirmed that [68Ga]Ga-PSMA-617 PET/CT could reliably detect CAR-ΔPSMA T cells in vitro and in vivo in solid tumors, laying the foundation for the monitoring CAR T cell therapy in the future.
Keywords: CAR T cells; PET/CT; PSMA; Reporter gene; Solid tumors.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Construction of truncated PSMA as a PET reporter gene for CAR T cell trafficking.J Leukoc Biol. 2024 Feb 23;115(3):476-482. doi: 10.1093/jleuko/qiad127. J Leukoc Biol. 2024. PMID: 37943840
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.Eur Urol Focus. 2021 Mar;7(2):472-478. doi: 10.1016/j.euf.2019.06.008. Epub 2019 Jun 18. Eur Urol Focus. 2021. PMID: 31227464 Free PMC article.
-
68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis.Hell J Nucl Med. 2022 Sep-Dec;25(3):297-311. doi: 10.1967/s002449912525. Hell J Nucl Med. 2022. PMID: 36576728
Cited by
-
Biomarker-driven molecular imaging probes in radiotherapy.Theranostics. 2024 Jul 2;14(10):4127-4146. doi: 10.7150/thno.97768. eCollection 2024. Theranostics. 2024. PMID: 38994026 Free PMC article. Review.
-
PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.Cancer J. 2024 May-Jun 01;30(3):153-158. doi: 10.1097/PPO.0000000000000722. Cancer J. 2024. PMID: 38753749 Free PMC article. Review.
-
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2504950122. doi: 10.1073/pnas.2504950122. Epub 2025 Jun 10. Proc Natl Acad Sci U S A. 2025. PMID: 40493195
-
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025. Front Immunol. 2025. PMID: 40612954 Free PMC article. Review.
-
Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro.Adv Sci (Weinh). 2025 Jul;12(28):e2506746. doi: 10.1002/advs.202506746. Epub 2025 May 11. Adv Sci (Weinh). 2025. PMID: 40349166 Free PMC article.
References
-
- Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59. https://doi.org/10.1038/s41568-021-00347-z . - DOI - PubMed - PMC
-
- June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5. https://doi.org/10.1126/science.aar6711 . - DOI - PubMed
-
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45–56. https://doi.org/10.1056/NEJMoa1804980 . - DOI - PubMed
-
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447 . - DOI - PubMed - PMC
-
- Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. https://doi.org/10.1016/S0140-6736(21)01222-8 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous